Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma

Makoto Kawamoto, Masayo Umebayashi, Hiroto Tanaka, Norihiro Koya, Sinichiro Nakagawa, Ken Kawabe, Hideya Ohnishi, Masafumi Nakamura, Takashi Morisaki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background/Aim: Metronidazole (MNZ) is a common antibiotic that exerts disulfiram-like effects when taken together with alcohol. However, the relationship between MNZ and aldehyde dehydrogenase (ALDH) activity remains unclear. This study investigated whether MNZ reduces cancer stemness by suppressing ALDH activity and accordingly reducing the malignancy of cholangiocarcinoma (CCA). Materials and Methods: We developed gemcitabine (GEM)-resistant TFK-1 cells and originally established CCA cell line from a patient with GEM-resistant CCA. Using these cell lines, we analyzed the impacts of MNZ for cancer stem cell markers, invasiveness, and chemosensitivity. Results: MNZ reduced ALDH activity in GEM-resistant CCA cells, leading to decreased invasiveness and enhanced chemosensitivity. MNZ diminished the invasiveness by inducing mesenchymal-epithelial transition and enhancing chemosensitivity by increasing ENT1 (equilibrative nucleoside transporter 1) and reducing RRM1 (ribonucleotide reductase M1). Conclusion: MNZ reduced cancer stemness in GEM-resistant CCA cells. Combined GEM and MNZ would be a promising therapeutic strategy for cancer stem-like CAA.

Original languageEnglish
Pages (from-to)2739-2748
Number of pages10
JournalAnticancer research
Volume38
Issue number5
DOIs
Publication statusPublished - May 1 2018

Fingerprint

gemcitabine
Cholangiocarcinoma
Metronidazole
Aldehyde Dehydrogenase
Neoplasms
Therapeutics
Equilibrative Nucleoside Transporter 1
Ribonucleotide Reductases
Disulfiram
Cell Line
Epithelial-Mesenchymal Transition
Neoplastic Stem Cells

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Kawamoto, M., Umebayashi, M., Tanaka, H., Koya, N., Nakagawa, S., Kawabe, K., ... Morisaki, T. (2018). Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma. Anticancer research, 38(5), 2739-2748. https://doi.org/10.21873/anticanres.12516

Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma. / Kawamoto, Makoto; Umebayashi, Masayo; Tanaka, Hiroto; Koya, Norihiro; Nakagawa, Sinichiro; Kawabe, Ken; Ohnishi, Hideya; Nakamura, Masafumi; Morisaki, Takashi.

In: Anticancer research, Vol. 38, No. 5, 01.05.2018, p. 2739-2748.

Research output: Contribution to journalArticle

Kawamoto, Makoto ; Umebayashi, Masayo ; Tanaka, Hiroto ; Koya, Norihiro ; Nakagawa, Sinichiro ; Kawabe, Ken ; Ohnishi, Hideya ; Nakamura, Masafumi ; Morisaki, Takashi. / Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma. In: Anticancer research. 2018 ; Vol. 38, No. 5. pp. 2739-2748.
@article{54f9939e2a964b70ab20807adde70b2e,
title = "Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma",
abstract = "Background/Aim: Metronidazole (MNZ) is a common antibiotic that exerts disulfiram-like effects when taken together with alcohol. However, the relationship between MNZ and aldehyde dehydrogenase (ALDH) activity remains unclear. This study investigated whether MNZ reduces cancer stemness by suppressing ALDH activity and accordingly reducing the malignancy of cholangiocarcinoma (CCA). Materials and Methods: We developed gemcitabine (GEM)-resistant TFK-1 cells and originally established CCA cell line from a patient with GEM-resistant CCA. Using these cell lines, we analyzed the impacts of MNZ for cancer stem cell markers, invasiveness, and chemosensitivity. Results: MNZ reduced ALDH activity in GEM-resistant CCA cells, leading to decreased invasiveness and enhanced chemosensitivity. MNZ diminished the invasiveness by inducing mesenchymal-epithelial transition and enhancing chemosensitivity by increasing ENT1 (equilibrative nucleoside transporter 1) and reducing RRM1 (ribonucleotide reductase M1). Conclusion: MNZ reduced cancer stemness in GEM-resistant CCA cells. Combined GEM and MNZ would be a promising therapeutic strategy for cancer stem-like CAA.",
author = "Makoto Kawamoto and Masayo Umebayashi and Hiroto Tanaka and Norihiro Koya and Sinichiro Nakagawa and Ken Kawabe and Hideya Ohnishi and Masafumi Nakamura and Takashi Morisaki",
year = "2018",
month = "5",
day = "1",
doi = "10.21873/anticanres.12516",
language = "English",
volume = "38",
pages = "2739--2748",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "5",

}

TY - JOUR

T1 - Combined gemcitabine and metronidazole is a promising therapeutic strategy for cancer stem-like cholangiocarcinoma

AU - Kawamoto, Makoto

AU - Umebayashi, Masayo

AU - Tanaka, Hiroto

AU - Koya, Norihiro

AU - Nakagawa, Sinichiro

AU - Kawabe, Ken

AU - Ohnishi, Hideya

AU - Nakamura, Masafumi

AU - Morisaki, Takashi

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Background/Aim: Metronidazole (MNZ) is a common antibiotic that exerts disulfiram-like effects when taken together with alcohol. However, the relationship between MNZ and aldehyde dehydrogenase (ALDH) activity remains unclear. This study investigated whether MNZ reduces cancer stemness by suppressing ALDH activity and accordingly reducing the malignancy of cholangiocarcinoma (CCA). Materials and Methods: We developed gemcitabine (GEM)-resistant TFK-1 cells and originally established CCA cell line from a patient with GEM-resistant CCA. Using these cell lines, we analyzed the impacts of MNZ for cancer stem cell markers, invasiveness, and chemosensitivity. Results: MNZ reduced ALDH activity in GEM-resistant CCA cells, leading to decreased invasiveness and enhanced chemosensitivity. MNZ diminished the invasiveness by inducing mesenchymal-epithelial transition and enhancing chemosensitivity by increasing ENT1 (equilibrative nucleoside transporter 1) and reducing RRM1 (ribonucleotide reductase M1). Conclusion: MNZ reduced cancer stemness in GEM-resistant CCA cells. Combined GEM and MNZ would be a promising therapeutic strategy for cancer stem-like CAA.

AB - Background/Aim: Metronidazole (MNZ) is a common antibiotic that exerts disulfiram-like effects when taken together with alcohol. However, the relationship between MNZ and aldehyde dehydrogenase (ALDH) activity remains unclear. This study investigated whether MNZ reduces cancer stemness by suppressing ALDH activity and accordingly reducing the malignancy of cholangiocarcinoma (CCA). Materials and Methods: We developed gemcitabine (GEM)-resistant TFK-1 cells and originally established CCA cell line from a patient with GEM-resistant CCA. Using these cell lines, we analyzed the impacts of MNZ for cancer stem cell markers, invasiveness, and chemosensitivity. Results: MNZ reduced ALDH activity in GEM-resistant CCA cells, leading to decreased invasiveness and enhanced chemosensitivity. MNZ diminished the invasiveness by inducing mesenchymal-epithelial transition and enhancing chemosensitivity by increasing ENT1 (equilibrative nucleoside transporter 1) and reducing RRM1 (ribonucleotide reductase M1). Conclusion: MNZ reduced cancer stemness in GEM-resistant CCA cells. Combined GEM and MNZ would be a promising therapeutic strategy for cancer stem-like CAA.

UR - http://www.scopus.com/inward/record.url?scp=85046777184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85046777184&partnerID=8YFLogxK

U2 - 10.21873/anticanres.12516

DO - 10.21873/anticanres.12516

M3 - Article

VL - 38

SP - 2739

EP - 2748

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 5

ER -